FRAX1036

FRAX1036

Biochem/physiol Actions

FRAX1036 is a potent, group I-selective p21-activated kinase (PAK) inhibitor (PAK1/4 Ki = 23 nM/1.4 µM; PAK1/4 IC50 = 2 nM/>500 nM; >96% PAK1/2/3 inhibition vs. 5.1%/8.2%/22.2% PAK4/5/6 inhibition at 1 µM) with significant inhibitory activity toward only 11 other kinases at a high concentration of 1 µM (78.7-100% inhibition) among a panel of 240. FRAX1036 exhibits higher antiproliferation activity in PAK negative regulator NF2-deficient meningioma cultures (NF2-/- Ben-Men-1/KT21-MG1 IC50 = 1.888/1.991 µM vs.NF2+/+ MN328/MN525 IC50 = 4.239/3.296 µM) by inhibiting cellular PAK autophosphorylation and downstream signaling events. When administered orally in a murine orthotopic meningioma model, FRAX1036 effectively suppresses the growth of established KT21 and Ben-Men tumors in vivo (30 mg/kg/d p.o.).

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3576592 FRAX1036 white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£486.11 (exc VAT) per EACH
-
+
3576593 FRAX1036 white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£120.62 (exc VAT) per EACH
-
+